Harm Reduction Group (NGM:NOHARM) First Quarter 2024 Results
Key Financial Results
- Revenue: kr80.3m (up 96% from 1Q 2023).
- Net loss: kr10.1m (loss widened by 125% from 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Harm Reduction Group Earnings Insights
Looking ahead, revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 2.3% decline forecast for the Tobacco industry in Europe.
Performance of the market in Sweden.
The company's shares are down 1.5% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 4 warning signs for Harm Reduction Group (of which 3 are a bit unpleasant!) you should know about.
Valuation is complex, but we're here to simplify it.
Discover if Harm Reduction Group might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NGM:NOHARM
Harm Reduction Group
Provides legal nicotine products as a substitute for the harmful tobacco smoking.
Slight with mediocre balance sheet.
